Equity Details
Price & Market Data
Price: $5.50
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $5,085,564,081
Daily Volume: 0
Performance Metrics
1 Week: 14.11%
1 Month: 14.11%
3 Months: -8.57%
6 Months: -5.17%
1 Year: 48.65%
YTD: -9.09%
About H. Lundbeck A/S (HLUBF)
Get all information on H. Lundbeck A/S (HLUBF). Price: 5.50, daily change: $0.00 / 0.00%. Market cap: 5,085,564,081. Performance for 1-week, 1-month, 52-week.
Company Details
Employees: 5214
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Denmark
Details
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.